Special Issue

Drug Discovery and Development Targeting NMDA Receptors

Message from the Guest Editor

Excitement in the NMDA receptor antagonist field was rekindled by the USA FDA approval of Memantine for the treatment of Alzheimer's disease in 2003. This special issue is a follow on of our special issue of a decade ago titled "NMDA Receptor Antagonists for the Treatment of CNS Disorders" in this journal. As predicted then, there have been several positive developments in the field and thus a revised look is warranted. An example is the approval of NMDAR antagonist ketamine for treatment resistant depression. It represents a new mechanism for treatment of depression in over 3 decades. Another antagonist, Dextromethorphan has been approved for depression. Other NMDAR antagonists are being examined for treatment of pain. While all glutamate receptors are possible drug targets, the NMDA receptor has been particularly attractive for many reasons, including feasibility and possible options of use. The goal of this special issue is to examine progress in, current and future prospects in CNS drug discovery through this receptor. Prof. Dr. Adeboye Adejar

Guest Editor

Prof. Dr. Adeboye Adejare

Philadelphia College of Pharmacy, St. Joseph's University, Philadelphia, PA, USA

Deadline for manuscript submissions

closed (24 February 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/180035

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

